Company Number: 15153608

Analysis Date: 2025-07-20 18:29 UTC

1. Credit Opinion:
   APPROVE with caution. HOUSA PATHOLOGY SERVICES LIMITED is a newly incorporated micro-entity with a clean and current filing history and no overdue accounts or returns. The company’s balance sheet shows a positive net asset position and working capital, indicating initial financial stability. However, as a start-up in the specialist medical practice sector with no employees besides directors and limited financial history, ongoing monitoring is essential. The directors are NHS doctors, implying relevant expertise and potential stability.

2. Financial Strength:
   The company reported fixed assets of £3,043 and current assets of £24,699 against current liabilities of £8,307 as of 30 September 2024, yielding net current assets of £16,392 and shareholders’ funds of £19,435. This indicates a solid balance sheet for a micro-entity start-up, with net assets reflecting initial capital investment or retained earnings. Absence of long-term liabilities improves financial resilience. However, the small asset base and lack of detailed profit and loss information limit a full assessment of profitability or capital structure.

3. Cash Flow Assessment:
   Current assets significantly exceed current liabilities, suggesting adequate short-term liquidity and working capital to meet immediate obligations. The company’s lack of employees and relatively low liabilities reduce cash burn risk. However, without detailed cash flow statements or profit and loss data, it is unclear how recurring operational cash flows support ongoing expenses. The directors’ professional background and control imply possible personal financial support if needed in early stages.

4. Monitoring Points:

• Progression in revenue generation and profitability once trading is fully underway.
• Maintenance of positive working capital and liquidity ratios in subsequent filings.
• Any increase in liabilities or overdrafts that could strain liquidity.
• Compliance with ongoing filing deadlines and regulatory requirements.
• Changes in director or PSC status that might affect governance or control.